胃促生长素和肥胖抑制素在非酒精性脂肪性肝病发展中的作用

Role of ghrelin and obestatin in the progression of nonalcoholic fatty liver disease

非酒精性脂肪性肝病(NAFLD)是一种多因素所致的疾病,可进展为肝硬化和肝细胞癌。目前,NAFLD的发病机制尚未完全清楚,并且临床上尚未有有效的治疗药物,寻找副作用少、能够有效延缓或者逆转疾病进展的新药尤为重要。研究表明,由胃组织产生的相关激素在参与维持能量稳态和肥胖的调节中具有多种效应,胃底基因中的炎症相关基因表达水平与肝病的严重程度一致,因此,有理由认为胃是导致NAFLD的重要参与者之一。总结了胃产生的胃促生长素和肥胖抑制素在NAFLD发展中的作用,为NAFLD的发病机制提供了一个新的观点,并为其治疗提供了一个新的方向。

Nonalcoholic fatty liver disease(NAFLD)is a disease caused by multiple factors and can progress to liver cirrhosis and hepatocellular carcinoma.At present,the pathogenesis of NAFLD remains unclear and there are still no effective therapeutic drugs in clinical practice;therefore,it is particularly important to search for new therapeutic drugs that have few side effects and can effectively delay or reverse disease progression.Some studies have shown that related hormones produced by gastric tissue have a variety of effects in the regulation of energy homeostasis and obesity,and the expression level of inflammation-related genes in gastric fundus is consistent with the severity of liver disease;thus we have reason to believe that the stomach is one of the important participants in NAFLD.This article summarizes the role of ghrelin and obestatin produced by the stomach in the progression of NAFLD,which provides a new idea for the pathogenesis of NAFLD and a new direction for treatment.